Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 7/20 | 0.57 |
| ▸ | CYP4Z1 | Q86W10 | 5/20 | 0.54 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311179 | 1.00 | SLC9A1 (0.57) | SLC9A1CYP4Z1ASAH1KEAP1TLR8 | |
| Bromide SCHEMBL28866483 | 0.95 | SLC9A1 (0.54) | SLC9A1CYP4Z1ASAH1KEAP1TLR8 | |
| SCHEMBL24192397 | 0.92 | SLC9A1 (0.52) | SLC9A1CYP4Z1ASAH1KEAP1TLR8 | |
| Bromide SCHEMBL28257701 | 0.91 | SLC9A1 (0.52) | SLC9A1CYP4Z1ASAH1KEAP1TLR8 | |
| SCHEMBL27714321 | 0.87 | SLC9A1 (0.56) | SLC9A1CYP4Z1ASAH1KEAP1TLR8 | |
| SCHEMBL25613143 | 0.85 | SLC9A1 (0.55) | SLC9A1CYP4Z1ASAH1KEAP1MGAM | |
| SCHEMBL31066856 | 0.85 | SLC9A1 (0.55) | SLC9A1CYP4Z1ASAH1KEAP1MGAM | |
| SCHEMBL22651915 | 0.85 | SLC9A1 (0.55) | SLC9A1CYP4Z1ASAH1KEAP1MGAM | |
| SCHEMBL30634969 | 0.83 | SLC9A1 (0.52) | SLC9A1CYP4Z1ASAH1KEAP1TLR8 | |
| SCHEMBL29244717 | 0.83 | SLC9A1 (0.52) | SLC9A1CYP4Z1ASAH1KEAP1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708381-B2 | Inhibitors of androgen receptor signaling | XAVIER UNIVERSITY OF LOUISIANA (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708381-B2 | Inhibitors of androgen receptor signaling | AR, ESRRA, ESRRB | SLC9A1 4483/4885CYP4Z1 3293/4885ASAH1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.